Therapeutic Targets in CAR NK-Cell Therapy

Natural killer (NK) cells are immune cells capable of killing target cells and can be genetically modified to express chimeric antigen receptors (CARs). CAR NK-cell therapy is an innovative type of cancer immunotherapy for solid tumors and hematological malignancies.

Functionally, CAR-NK cells kill target cancer cells in a CAR-dependent manner. Compared to traditional CAR-T cells, CAR-NK cells and unmodified NK cells offer safety advantages. The limited lifespan of CAR-NK cells greatly lowers the risk of on-target/off-tumor toxicity to normal cells. Additionally, reduced risk for alloreactivity and Graft versus host disease (GvHD) allows CAR-NK cells to be generated from a variety of sources, including NK92 cells, peripheral blood mononuclear cells (PBMCs), umbilical cord blood (UCB), and induced pluripotent stem cells (iPSCs).

Sino Biological provides a variety of CAR-NK-related proteins and antibodies with superior quality.